IOVA
Iovance Biotherapeutics, Inc.
Biotechnology
Market Cap$1.68B
5Y Perf.-87.3%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
IOVA vs TMO
Revenue, margins, valuation, and 5-year total return — side by side.
TMO
Thermo Fisher Scientific Inc.
Medical - Diagnostics & Research
Market Cap$175.76B
5Y Perf.+35.4%
IOVA vs TMO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | IOVA | TMO |
|---|---|---|
| Industry | Biotechnology | Medical - Diagnostics & Research |
| Market Cap | $1.68B | $175.76B |
| Revenue (TTM) | $264M | $45.20B |
| Net Income (TTM) | $-391M | $6.86B |
| Gross Margin | 97.2% | 39.4% |
| Operating Margin | -153.1% | 17.8% |
| Forward P/E | — | 19.0x |
| Total Debt | $48M | $40.85B |
| Cash & Equiv. | $163M | $9.86B |
IOVA vs TMO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
IOVA
TMO
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Iovance Biotherapeu… (IOVA) | 100 | 12.7 | -87.3% |
| Thermo Fisher Scien… (TMO) | 100 | 135.4 | +35.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: IOVA vs TMO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TMO leads in 4 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Iovance Biotherapeutics, Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
IOVA
Iovance Biotherapeutics, Inc.
The Growth Play
IOVA is the clearest fit if your priority is growth exposure and sleep-well-at-night.
- Rev growth 60.6%, EPS growth 14.8%
- Lower volatility, beta 2.01, Low D/E 6.9%, current ratio 3.20x
- 60.6% revenue growth vs TMO's 3.9%
Best for: growth exposure and sleep-well-at-night
TMO
Thermo Fisher Scientific Inc.
The Income Pick
TMO carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 8 yrs, beta 1.10, yield 0.4%
- 229.1% 10Y total return vs IOVA's -21.5%
- Beta 1.10, yield 0.4%, current ratio 1.89x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | IOVA | 60.6% revenue growth vs TMO's 3.9% |
| Quality / Margins | TMO | 15.2% margin vs IOVA's -148.4% |
| Stability / Safety | TMO | Beta 1.10 vs IOVA's 2.01 |
| Dividends | TMO | 0.4% yield; 8-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | IOVA | +31.9% vs TMO's +16.6% |
| Efficiency (ROA) | TMO | 6.4% ROA vs IOVA's -42.8%, ROIC 7.5% vs -48.9% |
IOVA vs TMO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
IOVA vs TMO — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLTMOLAGGINGIOVA
IOVAIovance Biotherapeuti…
1leads
TMOThermo Fisher Scienti…
4leads
6 Total Categories
CATEGORYLEADERvs IOVAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
IOVA2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
TMO5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
TMO4/6
Risk & VolatilityBeta, volatility, and downside exposure
TMO2/2
Analyst OutlookRatings, price targets, and dividends
TMO1/1
Income & Cash Flow (Last 12 Months)
Evenly matched — IOVA and TMO each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TMO is the larger business by revenue, generating $45.2B annually — 171.5x IOVA's $264M. TMO is the more profitable business, keeping 15.2% of every revenue dollar as net income compared to IOVA's -148.4%. On growth, IOVA holds the edge at +17.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | IOVAIovance Biotherap… | TMOThermo Fisher Sci… |
|---|---|---|
| RevenueTrailing 12 months | $264M | $45.2B |
| EBITDAEarnings before interest/tax | -$367M | $10.5B |
| Net IncomeAfter-tax profit | -$391M | $6.9B |
| Free Cash FlowCash after capex | -$336M | $6.7B |
| Gross MarginGross profit ÷ Revenue | +97.2% | +39.4% |
| Operating MarginEBIT ÷ Revenue | -153.1% | +17.8% |
| Net MarginNet income ÷ Revenue | -148.4% | +15.2% |
| FCF MarginFCF ÷ Revenue | -127.6% | +14.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | +17.7% | +6.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +42.3% | +11.3% |
Evenly matched — IOVA and TMO each lead in 3 of 6 comparable metrics.
Valuation Metrics
IOVA leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | IOVAIovance Biotherap… | TMOThermo Fisher Sci… |
|---|---|---|
| Market CapShares × price | $1.7B | $175.8B |
| Enterprise ValueMkt cap + debt − cash | $1.6B | $206.8B |
| Trailing P/EPrice ÷ TTM EPS | -3.75x | 26.66x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 19.04x |
| PEG RatioP/E ÷ EPS growth rate | — | 12.62x |
| EV / EBITDAEnterprise value multiple | — | 18.99x |
| Price / SalesMarket cap ÷ Revenue | 6.39x | 3.94x |
| Price / BookPrice ÷ Book value/share | 2.09x | 3.33x |
| Price / FCFMarket cap ÷ FCF | — | 27.93x |
IOVA leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
TMO leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
TMO delivers a 13.2% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $-56 for IOVA. IOVA carries lower financial leverage with a 0.07x debt-to-equity ratio, signaling a more conservative balance sheet compared to TMO's 0.76x. On the Piotroski fundamental quality scale (0–9), TMO scores 6/9 vs IOVA's 5/9, reflecting solid financial health.
| Metric | IOVAIovance Biotherap… | TMOThermo Fisher Sci… |
|---|---|---|
| ROE (TTM)Return on equity | -56.0% | +13.2% |
| ROA (TTM)Return on assets | -42.8% | +6.4% |
| ROICReturn on invested capital | -48.9% | +7.5% |
| ROCEReturn on capital employed | -51.6% | +9.1% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 6 |
| Debt / EquityFinancial leverage | 0.07x | 0.76x |
| Net DebtTotal debt minus cash | -$115M | $31.0B |
| Cash & Equiv.Liquid assets | $163M | $9.9B |
| Total DebtShort + long-term debt | $48M | $40.9B |
| Interest CoverageEBIT ÷ Interest expense | — | 5.89x |
TMO leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
TMO leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TMO five years ago would be worth $10,211 today (with dividends reinvested), compared to $1,430 for IOVA. Over the past 12 months, IOVA leads with a +31.9% total return vs TMO's +16.6%. The 3-year compound annual growth rate (CAGR) favors TMO at -4.2% vs IOVA's -16.7% — a key indicator of consistent wealth creation.
| Metric | IOVAIovance Biotherap… | TMOThermo Fisher Sci… |
|---|---|---|
| YTD ReturnYear-to-date | +62.3% | -20.1% |
| 1-Year ReturnPast 12 months | +31.9% | +16.6% |
| 3-Year ReturnCumulative with dividends | -42.2% | -11.9% |
| 5-Year ReturnCumulative with dividends | -85.7% | +2.1% |
| 10-Year ReturnCumulative with dividends | -21.5% | +229.1% |
| CAGR (3Y)Annualised 3-year return | -16.7% | -4.2% |
TMO leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
TMO leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
TMO is the less volatile stock with a 1.10 beta — it tends to amplify market swings less than IOVA's 2.01 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | IOVAIovance Biotherap… | TMOThermo Fisher Sci… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.01x | 1.10x |
| 52-Week HighHighest price in past year | $5.63 | $643.99 |
| 52-Week LowLowest price in past year | $1.64 | $385.46 |
| % of 52W HighCurrent price vs 52-week peak | +72.6% | +73.4% |
| RSI (14)Momentum oscillator 0–100 | 60.8 | 39.8 |
| Avg Volume (50D)Average daily shares traded | 16.3M | 1.9M |
TMO leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
TMO leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Wall Street rates IOVA as "Buy" and TMO as "Buy". Consensus price targets imply 38.4% upside for TMO (target: $655) vs -51.1% for IOVA (target: $2). TMO is the only dividend payer here at 0.36% yield — a key consideration for income-focused portfolios.
| Metric | IOVAIovance Biotherap… | TMOThermo Fisher Sci… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $2.00 | $654.67 |
| # AnalystsCovering analysts | 20 | 42 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% |
| Dividend StreakConsecutive years of raises | 1 | 8 |
| Dividend / ShareAnnual DPS | — | $1.69 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.7% |
TMO leads this category, winning 1 of 1 comparable metric.
Key Takeaway
TMO leads in 4 of 6 categories (Profitability & Efficiency, Total Returns). IOVA leads in 1 (Valuation Metrics). 1 tied.
Best OverallThermo Fisher Scientific In… (TMO)Leads 4 of 6 categories
Loading custom metrics...
IOVA vs TMO: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is IOVA or TMO a better buy right now?
For growth investors, Iovance Biotherapeutics, Inc.
(IOVA) is the stronger pick with 60. 6% revenue growth year-over-year, versus 3. 9% for Thermo Fisher Scientific Inc. (TMO). Thermo Fisher Scientific Inc. (TMO) offers the better valuation at 26. 7x trailing P/E (19. 0x forward), making it the more compelling value choice. Analysts rate Iovance Biotherapeutics, Inc. (IOVA) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — IOVA or TMO?
Over the past 5 years, Thermo Fisher Scientific Inc.
(TMO) delivered a total return of +2. 1%, compared to -85. 7% for Iovance Biotherapeutics, Inc. (IOVA). Over 10 years, the gap is even starker: TMO returned +229. 1% versus IOVA's -21. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — IOVA or TMO?
By beta (market sensitivity over 5 years), Thermo Fisher Scientific Inc.
(TMO) is the lower-risk stock at 1. 10β versus Iovance Biotherapeutics, Inc. 's 2. 01β — meaning IOVA is approximately 83% more volatile than TMO relative to the S&P 500. On balance sheet safety, Iovance Biotherapeutics, Inc. (IOVA) carries a lower debt/equity ratio of 7% versus 76% for Thermo Fisher Scientific Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — IOVA or TMO?
By revenue growth (latest reported year), Iovance Biotherapeutics, Inc.
(IOVA) is pulling ahead at 60. 6% versus 3. 9% for Thermo Fisher Scientific Inc. (TMO). On earnings-per-share growth, the picture is similar: Iovance Biotherapeutics, Inc. grew EPS 14. 8% year-over-year, compared to 7. 3% for Thermo Fisher Scientific Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — IOVA or TMO?
Thermo Fisher Scientific Inc.
(TMO) is the more profitable company, earning 15. 1% net margin versus -148. 4% for Iovance Biotherapeutics, Inc. — meaning it keeps 15. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TMO leads at 18. 2% versus -153. 1% for IOVA. At the gross margin level — before operating expenses — IOVA leads at 97. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is IOVA or TMO more undervalued right now?
Analyst consensus price targets imply the most upside for TMO: 38.
4% to $654. 67.
07Which pays a better dividend — IOVA or TMO?
In this comparison, TMO (0.
4% yield) pays a dividend. IOVA does not pay a meaningful dividend and should not be held primarily for income.
08Is IOVA or TMO better for a retirement portfolio?
For long-horizon retirement investors, Thermo Fisher Scientific Inc.
(TMO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 10), +229. 1% 10Y return). Iovance Biotherapeutics, Inc. (IOVA) carries a higher beta of 2. 01 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TMO: +229. 1%, IOVA: -21. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between IOVA and TMO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: IOVA is a small-cap high-growth stock; TMO is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(IOVA: 17.7% · TMO: 6.2%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.